Viatris (VTRS) Total Current Liabilities (2019 - 2026)
Viatris' (VTRS) quarterly Total Current Liabilities came in at $6.8 billion in Q1 2026, up 19.06% year-on-year from $5.7 billion in Q1 2025, and down 4.0% quarter-over-quarter from $7.1 billion in Q4 2025.
Viatris (VTRS) Total Current Liabilities (2019 - 2026) Analysis & Trends
Viatris' Total Current Liabilities history runs 8 years deep, the most recent figure standing at $6.8 billion for Q1 2026.
- On a quarterly basis, Total Current Liabilities rose 19.06% year-over-year to $6.8 billion in Q1 2026; TTM through Mar 2026 was $6.8 billion, a 19.06% increase from a year earlier, with the FY2025 full-year figure at $7.1 billion, up 22.75% from the prior year.
- Total Current Liabilities eased to $6.8 billion in Q1 2026 per VTRS's latest filing, from $7.1 billion in the prior quarter.
- Across five years, Total Current Liabilities topped out at $9.6 billion in Q1 2022 and bottomed at $5.7 billion in Q1 2025.
- The 5-year median for Total Current Liabilities is $7.1 billion (2025), against an average of $7.1 billion.
- Across the five-year window, Total Current Liabilities tumbled 36.66% in 2023 and advanced 27.04% in 2024, its largest moves.
- Year by year, Total Current Liabilities stood at $6.7 billion in 2022, then rose by 15.29% to $7.8 billion in 2023, then retreated by 25.69% to $5.8 billion in 2024, then grew by 22.75% to $7.1 billion in 2025, then fell by 4.0% to $6.8 billion in 2026.
- Per Business Quant, the three latest VTRS Total Current Liabilities figures stand at $6.8 billion (Q1 2026), $7.1 billion (Q4 2025), and $7.4 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 6.56 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.53 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 2.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 18.06 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 13.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 6.81 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 831.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.66 Bn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 215.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.81 Bn |
| Dec 31, 2025 | 7.09 Bn |
| Sep 30, 2025 | 7.36 Bn |
| Jun 30, 2025 | 7.13 Bn |
| Mar 31, 2025 | 5.72 Bn |
| Dec 31, 2024 | 5.78 Bn |
| Sep 30, 2024 | 7.51 Bn |
| Jun 30, 2024 | 7.71 Bn |
| Mar 31, 2024 | 7.76 Bn |
| Dec 31, 2023 | 7.78 Bn |
| Sep 30, 2023 | 6.83 Bn |
| Jun 30, 2023 | 6.52 Bn |
| Mar 31, 2023 | 6.11 Bn |
| Dec 31, 2022 | 6.75 Bn |
| Sep 30, 2022 | 6.52 Bn |
| Jun 30, 2022 | 7.68 Bn |
| Mar 31, 2022 | 9.64 Bn |
| Dec 31, 2021 | 9.88 Bn |
| Sep 30, 2021 | 10.10 Bn |
| Jun 30, 2021 | 10.13 Bn |